Clinical Trials Browser

OTHER × Lymphoma × tocilizumab × Clear all

NCT03588936 2021-10-11

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Phase 1 Terminated

LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes